Earnings summaries and quarterly performance for Beam Therapeutics.
Executive leadership at Beam Therapeutics.
Board of directors at Beam Therapeutics.
Research analysts who have asked questions during Beam Therapeutics earnings calls.
DG
Dae Gon Ha
Stifel
3 questions for BEAM
Also covers: ABEO, CRBP, EDIT +10 more
DC
Debjit Chattopadhyay
Guggenheim Securities
3 questions for BEAM
Also covers: BOLD, HOOK, IONS +5 more
Eric Joseph
JPMorgan Chase & Co.
3 questions for BEAM
Also covers: BLUE, ENTA, KYMR +9 more
HW
Huidong Wang
Barclays
3 questions for BEAM
Also covers: ALNY, BCRX, BLUE +15 more
KB
Konstantinos Biliouris
BMO Capital Markets
3 questions for BEAM
Also covers: ALNY, BMRN, LEGN +3 more
LI
Luca Issi
RBC Capital Markets
3 questions for BEAM
Also covers: ADVM, ALLO, ALNY +12 more
MF
Mani Foroohar
Leerink Partners
3 questions for BEAM
Also covers: ADVM, ALNY, ARWR +9 more
Michael Yee
Jefferies
3 questions for BEAM
Also covers: ABBV, ALLO, AMGN +18 more
Rick Bienkowski
Cantor Fitzgerald
3 questions for BEAM
Also covers: LEGN, NTLA
Samantha Semenkow
Citigroup Inc.
3 questions for BEAM
Also covers: ALLO, ARGX, CPRX +7 more
YZ
Yanan Zhu
Wells Fargo Securities
3 questions for BEAM
Also covers: ADAP, AFMD, ARCT +13 more
SC
Samantha Corwin
William Blair
2 questions for BEAM
Also covers: ALLO, KRYS, PTCT +3 more
SC
Sami Corwin
William Blair
1 question for BEAM
Also covers: ALLO, KRYS, MESO +5 more
Recent press releases and 8-K filings for BEAM.
Beam Therapeutics Provides Update on Clinical Programs and Financial Outlook
BEAM
New Projects/Investments
Guidance Update
Product Launch
- Beam Therapeutics reported a strong financial position with $1.25 billion in cash at year-end, extending its runway into 2029 to support the launch of Ristacel and the pivotal development of Beam 302.
- The company achieved FDA alignment on an accelerated approval pathway for Beam 302 (alpha-1 antitrypsin deficiency) in Q4, with updated Phase 1/2 clinical data anticipated by the end of Q1 2026.
- Beam plans to submit the Biologics License Application (BLA) for Ristacel (severe sickle cell disease) as early as the end of 2026, alongside initiating its commercial build.
- Further pipeline expansion includes disclosing an additional liver-targeted genetic disease program in the first half of 2026 and reporting initial clinical data for Beam 301 (Glycogen Storage Disease 1A) by year-end 2026.
Jan 14, 2026, 1:15 AM
Beam Therapeutics Announces Key Regulatory and Pipeline Milestones
BEAM
Guidance Update
New Projects/Investments
Product Launch
- Beam Therapeutics reported $1.25 billion in cash at year-end, providing a runway into 2029 to fund the launch of Ristacel and the pivotal development of Beam 302.
- The company plans to submit the Biologics License Application (BLA) for Ristacel (for sickle cell disease) as early as year-end 2026.
- For Beam 302 (for alpha-1 antitrypsin deficiency), Beam achieved FDA alignment on a potential accelerated approval pathway in Q4 and will report updated Phase 1/2 data and pivotal development timing by the end of Q1 2026.
- Beam expects to report initial clinical data for Beam 301 (for Glycogen Storage Disease 1A) by year-end 2026 and will disclose another liver-targeted genetic disease program in the first half of 2026.
- Partnerships have contributed over $900 million in non-dilutive funding to Beam over eight years.
Jan 14, 2026, 1:15 AM
Beam Therapeutics Provides Pipeline and Financial Outlook Update
BEAM
New Projects/Investments
Guidance Update
Product Launch
- Beam Therapeutics reported $1.25 billion in cash at year-end, providing a financial runway into 2029, which is expected to cover the anticipated launch of Risto-cel and the pivotal development plan for BEAM-302.
- The company plans to submit the Biologics License Application (BLA) package for Risto-cel (sickle cell disease) as early as the end of 2026.
- For BEAM-302 (alpha-1 antitrypsin deficiency), updated Phase I/II data is expected by the end of Q1 2026, following FDA alignment in Q4 2025 on a potential accelerated approval pathway.
- Beam plans to disclose another liver-targeted genetic disease program in the first half of 2026 and report initial data for BEAM-301 and GSDIa by year-end 2026.
Jan 14, 2026, 1:15 AM
Beam Therapeutics Provides Pipeline Updates and Extends Operating Runway
BEAM
Guidance Update
New Projects/Investments
Product Launch
- Beam Therapeutics ended 2025 with an estimated $1.25 billion in cash, cash equivalents, and marketable securities, which is projected to extend its operating runway into 2029.
- The company has reached alignment with the U.S. FDA on a potential accelerated approval pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) based on biomarker endpoints.
- A U.S. Biologics Licensing Application (BLA) submission for risto-cel (previously BEAM-101) for sickle cell disease is expected as early as year-end 2026.
- Beam plans to disclose a new liver-targeted genetic disease program in the first half of 2026 and expects to report initial clinical data for BEAM-301 in 2026.
Jan 12, 2026, 12:00 PM
Beam Therapeutics Provides Updates on Clinical Programs and Extends Operating Runway
BEAM
Guidance Update
New Projects/Investments
Product Launch
- Beam Therapeutics has aligned with the U.S. FDA on a potential accelerated approval pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) and anticipates submitting a Biologics Licensing Application (BLA) for risto-cel as early as year-end 2026.
- The company reported an estimated $1.25 billion in cash, cash equivalents, and marketable securities as of December 31, 2025, which includes $255.1 million from the acquisition of Orbital Therapeutics.
- This financial position is projected to extend Beam's operating runway into 2029, funding the anticipated launch of risto-cel and the pivotal development plan for BEAM-302.
- Beam plans to disclose a new liver-targeted genetic disease program in the first half of 2026 and anticipates reporting initial clinical data for BEAM-301 in 2026.
Jan 11, 2026, 10:00 PM
Beacon Therapeutics Closes Oversubscribed Series C Financing
BEAM
New Projects/Investments
Board Change
- Beacon Therapeutics Holdings Limited has raised over $75 million in an oversubscribed Series C financing round.
- The financing was led by new investor Life Sciences at Goldman Sachs Alternatives, with participation from the Retinal Degeneration Fund, and supported by existing investors.
- The funds will be used to advance laru-zova toward commercialization for the treatment of X-linked retinitis pigmentosa (XLRP), with pivotal data expected in the second half of 2026, and to accelerate the development of additional pipeline candidates.
- Colin Walsh, PhD, Managing Director, Life Sciences at Goldman Sachs Alternatives, has been appointed to Beacon Therapeutics' Board of Directors.
Jan 8, 2026, 12:00 PM
Beam Therapeutics receives cash from Orbital Therapeutics acquisition
BEAM
M&A
New Projects/Investments
Guidance Update
- Beam Therapeutics Inc. received $255.1 million in closing cash consideration from the acquisition of Orbital Therapeutics, Inc. by Bristol-Myers Squibb Company on December 8, 2025.
- Prior to the acquisition, Beam Therapeutics Inc. held 75 million shares of Orbital, representing an approximate 17% fully diluted ownership stake.
- The company is also eligible to receive up to an additional $26.3 million in cash consideration from potential escrow releases.
- Beam plans to provide an update on its anticipated cash runway, taking into account these proceeds, at the 2026 J.P. Morgan Healthcare Conference.
Dec 11, 2025, 9:30 PM
Beam Therapeutics to Present Updated Clinical Trial Data for Sickle Cell Disease
BEAM
New Projects/Investments
- Beam Therapeutics Inc. will present updated data from its BEACON Phase 1/2 clinical trial at the American Society of Hematology (ASH) Annual Meeting in December.
- The trial focuses on BEAM-101, a one-time, potentially disease-modifying base editing therapy for sickle cell disease with severe vaso-occlusive crises, a condition affecting approximately 8 million people worldwide.
- The presentations will highlight both clinical outcomes and manufacturing advances, including enhanced mobilization techniques for autologous CD34+ hematopoietic stem cells that are base-edited to increase fetal hemoglobin production.
Dec 9, 2025, 4:57 PM
BeOne Medicines' Sonrotoclax Receives FDA Priority Review
BEAM
Product Launch
New Projects/Investments
- The FDA has granted priority review to sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor developed by BeOne Medicines, for treating adults with relapsed or refractory mantle cell lymphoma (MCL).
- This designation is supported by data from a Phase 1/2 trial involving 125 patients, which demonstrated a high overall response rate and a manageable safety profile.
- BeOne Medicines is leveraging the FDA's Project Orbis to coordinate international regulatory submissions and expedite global approvals for sonrotoclax.
- BeOne Medicines is a commercial-stage biotech company with a CRO-free strategy for clinical development, and its core drug Brukinsa accounts for more than 60% of revenue.
Nov 26, 2025, 11:29 AM
Beam Therapeutics Provides Updates on BEAM-302, BEAM-101, and Financial Runway
BEAM
Guidance Update
New Projects/Investments
- Beam Therapeutics plans to provide a more comprehensive update on its BEAM-302 program for Alpha-1 Antitrypsin Deficiency (AATD) in early 2026, including data from higher dose cohorts and patients with liver involvement.
- For BEAM-302, the company aims for an accelerated approval path based on biomarker data, with a potential pivotal trial size of 50-100 patients and a timeline of 3-6 months for durability assessment.
- The BEAM-101 program for sickle cell disease shows a differentiated profile with the highest F upregulation and lowest hemoglobin S, along with faster neutrophil and platelet engraftment times and an optimized, automated manufacturing process requiring a median of one mobilization cycle.
- Beam Therapeutics reported a cash position of $1.1 billion as of the end of Q3, providing a cash runway into 2028.
Nov 19, 2025, 3:30 PM
Quarterly earnings call transcripts for Beam Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more